Patents by Inventor Timothy W. Corson

Timothy W. Corson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FERROCHELATASE INHIBITORS AND METHODS OF USE
    Publication number: 20250049804
    Abstract: The invention relates to a method of treatment of a patient with a ferrochelatase inhibitor, or a pharmaceutically acceptable salt thereof, or a derivative thereof. Also, the invention relates to a method of treatment of a patient with a ferrochelatase inhibitor that is a triazolopyrimidinone, or a derivative thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 28, 2024
    Publication date: February 13, 2025
    Inventors: Timothy W. CORSON, Kamakshi SISHTLA, Seung-Yong SEO, Bit LEE
  • Ferrochelatase inhibitors and methods of use
    Patent number: 12161642
    Abstract: The invention relates to a method of treatment of a patient with a ferrochelatase inhibitor, or a pharmaceutically acceptable salt thereof, or a derivative thereof. Also, the invention relates to a method of treatment of a patient with a ferrochelatase inhibitor that is a triazolopyrimidinone, or a derivative thereof, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: December 10, 2024
    Assignees: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, Gachon University of Industry—Academic Cooperation
    Inventors: Timothy W. Corson, Kamakshi Sishtla, Seung-Yong Seo, Bit Lee
  • TARGETING OCULAR DISEASES WITH NOVEL APE1/REF-1 INHIBITORS
    Publication number: 20230330046
    Abstract: Apurinic/apyrimidinic endonuclease 1 redox factor 1 (APE1/Ref-1) inhibitors for inhibiting ocular diseases are disclosed herein.
    Type: Application
    Filed: June 26, 2023
    Publication date: October 19, 2023
    Inventors: Mark R. Kelley, Timothy W. Corson
  • Targeting ocular diseases with novel APE1/Ref-1 inhibitors
    Patent number: 11723886
    Abstract: [[(2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methylidene]-N,N-diethylpentanamide] (APX2009) and (2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronapthalen-2-yl)methylidene]-N-methoxypentanamide] (APX2014) for inhibiting ocular diseases are disclosed herein.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: August 15, 2023
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Mark R. Kelley, Timothy W. Corson
  • PHARMACEUTICAL FORMULATIONS OF GRISEOFULVIN FOR LONG-TERM OCULAR DELIVERY
    Publication number: 20230248689
    Abstract: The present invention relates to pharmaceutical formulations for long-term ocular delivery of the active agents. The present invention further provides the long-term ocular delivery of griseofulvin with specific in vitro release profile. These formulations are used for the treatment of neovascular eye diseases and age-related macular degeneration (AMD). In particular, the present invention provides microparticles & nanoparticles of griseofulvin for the long-term ocular delivery and methods of preparation of such formulations.
    Type: Application
    Filed: June 24, 2021
    Publication date: August 10, 2023
    Applicants: PURDUE RESEARCH FOUNDATION, THE TRUSTEES OF INDIANA UNIVERSITY
    Inventors: Yoon Yeo, Dhawal Chobisa, Timothy W. Corson
  • TARGETING OCULAR DISEASES WITH NOVEL APE1/REF-1 INHIBITORS
    Publication number: 20210393556
    Abstract: [[(2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methylidene]-N,N-diethylpentanamide] (APX2009) and (2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronapthalen-2-yl)methylidene]-N-methoxypentanamide] (APX2014) for inhibiting ocular diseases are disclosed herein.
    Type: Application
    Filed: February 7, 2019
    Publication date: December 23, 2021
    Inventors: Mark R. Kelley, Timothy W. Corson
  • ANTIANGIOGENIC CHROMANE DERIVATIVE AND USES THEREOF
    Publication number: 20210379012
    Abstract: A novel chromane derivative, (3?-hydroxy-4?-ethoxybenzyl)-5,6,7-trimethoxy-2H-1-benzopyran (SH-17059 (1)) is disclosed herein. This chromane derivative has been found to inhibit blood vessel cell growth and proliferation, providing a promising treatment for ocular angiogenesis-mediated diseases.
    Type: Application
    Filed: April 29, 2019
    Publication date: December 9, 2021
    Inventors: Timothy W. Corson, Seung-Yong SEO, Bit Lee, Sianne SCHWIKKARO, Dulcie MULHOLLAND, Hannah WHITMORE
  • FERROCHELATASE INHIBITORS AND METHODS OF USE
    Publication number: 20210121465
    Abstract: The invention relates to a method of treatment of a patient with a ferrochelatase inhibitor, or a pharmaceutically acceptable salt thereof, or a derivative thereof. Also, the invention relates to a method of treatment of a patient with a ferrochelatase inhibitor that is a triazolopyrimidinone, or a derivative thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 30, 2019
    Publication date: April 29, 2021
    Inventors: Timothy W. CORSON, Kamakshi SISHTLA, Seung-Yong SEO, Bit LEE
  • Compounds for treatment of angiogenesis-mediated diseases
    Patent number: 10738024
    Abstract: Synthetic cremastranone and cremastranone analogs are disclosed. Additionally, methods for synthesizing cremastranone and cremastranone analogs are disclosed. Methods of treating ocular neovascularization disorders and treating angiogenesis-mediated disease are also disclosed.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: August 11, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Timothy W. Corson, Halesha D. Basavarajappa, Seung-Yong Seo, Bit Lee, Xiang Fei
  • Compounds for treatment of angiogenesis-mediated diseases
    Patent number: 10238627
    Abstract: Synthetic cremastranone and cremastranone analogs are disclosed. Additionally, methods for synthesizing cremastranone and cremastranone analogs are disclosed. Methods of treating ocular neovascularization disorders and treating angiogenesis-mediated disease are also disclosed.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 26, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Timothy W. Corson, Halesha D. Basavarajappa, Seung-Yong Seo, Bit Lee, Xiang Fei
  • COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
    Publication number: 20180177758
    Abstract: Synthetic cremastranone and cremastranone analogs are disclosed. Additionally, methods for synthesizing cremastranone and cremastranone analogs are disclosed. Methods of treating ocular neovascularization disorders and treating angiogenesis-mediated disease are also disclosed.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 28, 2018
    Inventors: Timothy W. Corson, Halesha D. Basavarajappa, Seung-Yong Seo, Bit Lee, Xiang Fei
  • COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
    Publication number: 20160060241
    Abstract: Synthetic cremastranone and cremastranone analogs are disclosed. Additionally, methods for synthesizing cremastranone and cremastranone analogs are disclosed. Methods of treating ocular neovascularization disorders and treating angiogenesis-mediated disease are also disclosed.
    Type: Application
    Filed: May 6, 2014
    Publication date: March 3, 2016
    Inventors: Timothy W. Corson, Halesha D. Basavarajappa, Seung-Yong Seo, Bit Lee, Xiang Fei